The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole
Satoshi Sobue(Kasugai Municipal Hospital), Angelika Weil, Keith Tan(Pfizer (United Kingdom)), Gary Layton(University of Geneva), V. Leclerc
Cited by 19
Related Papers
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
|CHEST Journal|2011|257
STARTS-2
|Circulation|2014|212